Microbiotica
Cambridge company developing microbiome-based medicines.
Microbiotica develops oral medicines made from selected gut bacteria. A 2016 spinout from the Wellcome Sanger Institute, it uses clinical and genomic data to choose bacterial strains for therapeutic development.
Last refreshed: 22 October 2026 · Appears in 1 active topic
Timeline for Microbiotica
Closed the first £36m of a Series C
UK Startups and Innovation: British Business Bank leads Microbiotica's £36m Series CBackground
Microbiotica develops live biotherapeutic products: medicines containing selected living bacteria. Based near Cambridge, it emerged from the Wellcome Sanger Institute in 2016. Its research connects the composition of the gut microbiome with clinical outcomes, using those associations to select strains for further development. [Company background](https://Microbiotica.com/Microbiotica-raises-36-million-48-million-in-series-c-financing-to-advance-pipeline-into-phase-2-clinical-development/)
The company's platform combines a collection of bacterial cultures, a reference genome database, bioinformatics and machine learning. These tools help identify bacterial signatures in clinical trial data. Its therapeutic research includes inflammatory bowel disease and cancer immunotherapy. MB310 is its oral bacterial candidate for ulcerative colitis, while MB097 is being investigated in advanced melanoma. Both belong to a research programme in which clinical testing determines whether selected bacteria can produce useful treatment effects.
What is Microbiotica using its £36m financing for?
Who led Microbiotica's Series C?
What does MB310 contain?
Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 22 October 2026. Editorial standards.